NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 2.1% and is now trading at $474.69. View which stocks have been mosted impacted by Coronavirus.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its quarterly earnings data on Thursday, February, 6th. The biopharmaceutical company reported $7.50 EPS for the quarter, beating analysts' consensus estimates of $6.03 by $1.47. The biopharmaceutical company earned $2.17 billion during the quarter, compared to analysts' expectations of $2.10 billion. Regeneron Pharmaceuticals had a net margin of 26.91% and a return on equity of 24.14%. The company's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period last year, the company posted $6.84 earnings per share. View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals declared that its Board of Directors has approved a stock repurchase program on Tuesday, November 5th 2019, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 2.9% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued.

24 Wall Street analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $550.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $460.13 in the next twelve months. This suggests that the stock has a possible downside of 3.1%. View analysts' price targets for Regeneron Pharmaceuticals.

Media stories about REGN stock have trended very positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutRegeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 2,558,900 shares, a drop of 11.1% from the February 27th total of 2,880,000 shares. Based on an average daily volume of 1,294,900 shares, the days-to-cover ratio is presently 2.0 days. Currently, 3.1% of the shares of the stock are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Biogen (BIIB), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Alphabet (GOOG), Micron Technology (MU) and Broadcom (AVGO).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $474.69.

Regeneron Pharmaceuticals has a market capitalization of $52.23 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe. View additional information about Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]